CURE Pharmaceutical Holding Corp. announced that it has appointed Alex Katz as Chief Financial Officer of the company beginning on November 15, 2018. In connection with the appointment of Mr. Katz as Chief Financial Officer, Mark Udell, Chief Financial Officer of the company since November 2016, resigned from such position, effective November 15, 2018, and will serve as the company's Chief Accounting Officer.

Mr. Katz is an experienced C-Level executive, consultant and a General Partner of two associated New York venture capital funds, ff Venture Capital and Differential Venture Partners. He has significant experience as an attorney and a CPA and has been working with seed, early-stage and growth companies for over 30 years. Mr. Katz has provided professional services to a variety of companies, including those engaged in manufacturing, distribution, technology, construction and service companies.

In addition, Mr. Katz also serves as Co-Founder and Managing Partner of recently formed Differential Venture Partners.